Form 4: KalVista Director Sells Options Post-Merger

KalVista Pharmaceuticals director William Fairey disposed of stock options following the company's acquisition by Chiesi Farmaceutici S.p.A. for $27.00 per share.

Summary

• Director William Fairey disposed of 57,000 stock options in KalVista Pharmaceuticals, Inc. on June 11, 2026.
• This disposition was a direct result of the Agreement and Plan of Merger dated April 29, 2026, under which KalVista was acquired by Chiesi Farmaceutici S.p.A.
• Chiesi's subsidiary, Skyline Merger Sub, Inc., completed a cash tender offer to acquire all outstanding common stock of KalVista for $27.00 per share.
• The merger became effective on June 11, 2026, at which point KalVista became a wholly owned subsidiary of Chiesi Farmaceutici S.p.A.
• Stock options with an exercise price less than $27.00 were fully vested, cancelled, and converted into a cash payment equal to the difference between the merger consideration and the exercise price, multiplied by the number of shares.
• Stock options with an exercise price equal to or greater than $27.00 were automatically cancelled for no consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event for KalVista shareholders and in-the-money option holders, as it represents the successful completion of an acquisition providing a cash exit at a defined price. The company's independent public trading status has ceased.

Positives

• The merger provided a cash payout for in-the-money stock options, benefiting option holders like Mr. Fairey.
• Shareholders received $27.00 per share in cash, representing a clear exit strategy and liquidity for their investment.

Negatives

• Options with an exercise price equal to or greater than the $27.00 merger consideration were cancelled for no value.
• KalVista Pharmaceuticals ceased to be an independent publicly traded entity, becoming a wholly owned subsidiary.

Future Outlook

The filing indicates KalVista Pharmaceuticals, Inc. has been acquired and is now a wholly owned subsidiary of Chiesi Farmaceutici S.p.A., implying its future operations will be integrated within the parent company's structure.

Industry Context

StockSavvy.ai notes that the acquisition of KalVista Pharmaceuticals by Chiesi Farmaceutici S.p.A. reflects a broader trend in the pharmaceutical industry where larger players seek to acquire innovative smaller companies to expand their pipeline and market presence, particularly in specialized therapeutic areas.

Comparison to Industry Standards

• This transaction is a standard cash-out merger for a publicly traded company, where shareholders receive a fixed cash price per share.
• The treatment of stock options, where in-the-money options are cashed out and out-of-the-money options are cancelled, is a common practice in such acquisitions.
• Specific comparable companies or projects are not detailed in this Form 4, as it focuses on an individual's transaction post-merger.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $27.00 per share in cash, providing liquidity and a defined return on their investment.
• Option Holders (in-the-money): Received cash payments for the intrinsic value of their options.
• Option Holders (out-of-the-money): Options were cancelled for no consideration.
• Employees: Implied integration into Chiesi Farmaceutici S.p.A., which may lead to changes in employment terms or organizational structure.

Next Steps

• KalVista Pharmaceuticals will operate as a wholly owned subsidiary of Chiesi Farmaceutici S.p.A., with its operations integrated into the parent company.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Chiesi Farmaceutici, Merger, Acquisition, Tender Offer, Stock Options, Form 4, Insider Transaction, William Fairey